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Abstract
Background: Prompt administration of adequate empiric antimicrobial therapy is a major determinant influencing the 
outcome of serious infections. The objective of this study was to describe empiric antimicrobial therapy employed and 
assess its effect on the outcome of patients bacteremic with extended-spectrum beta-lactamase (ESBL) producing 
Escherichia coli and Klebsiella pneumoniae.
Findings: A retrospective surveillance study of all patients with bacteremias caused by ESBL-producing E. coli and K. 
pneumoniae (EK-ESBL) from 2000-2007 in the Calgary Health Region was conducted. Data were available for 79 
episodes of bacteremia among 76 patients. Forty-four (56%) were male, the median age was 70.0 yrs [interquartile 
range (IQR) 60.6-70.1 yrs], and 72 (91%) episodes were E. coli. Seventy-four episodes (94%) were treated with empiric 
therapy within the first 48 hours. A non-statistically significant increased mortality occurred in those treated empirically 
with a beta-lactam/beta-lactamase inhibitor combination (6/16; 38% vs. 10/53; 18%; p = 0.063) while empiric 
carbapenem therapy was associated with lower mortality (0/10 died vs. 16/53 (30%), p = 0.089). Only 42 (53%) episodes 
received adequate therapy within the first 48 hours. The median time to first adequate antibiotic therapy was 41.0 
hours [IQR 5.8-59.5] (n = 75). The case-fatality rate was not different among those that received adequate compared to 
inadequate therapy by 48 hours as compared to inadequate empiric therapy (9/42; 21% vs. 7/37; 19%; p = 1.0).
Conclusion: Inadequate empiric therapy is common among patients with EK-ESBL bacteremia in our region but was 
not associated with adverse mortality outcome.
Introduction
Organisms elaborating extended-spectrum beta-lactama-
ses (ESBL) are now found worldwide [1]. Bloodstream
infections caused by these microbes are increasing in the
community [2,3] and in hospitals [4-6]. These organisms
are typically multi-drug resistant [7] and the risk of inade-
quate empiric therapy [8-11] while awaiting susceptibility
results is high. ESBL-bacteremias are also a risk factor for
adverse outcome [10,11]. Previous studies have typically
been conducted in highly selected populations including
specific age ranges, location of acquisition (i.e. commu-
nity or hospital). Furthermore, these infections have typi-
cally been assessed in tertiary care referral centres. These
results may not reflect practices in populations at large
and generalization elsewhere may be limited.
Few studies have included a broad range of ages, loca-
tion of acquisition, and multiple centres, and none have
been from Canada. It was therefore of interest to describe
the empiric therapy of bacteremias caused by Escherichia
coli and Klebsiella pneumonia elaborating ESBL enzymes
(EK-ESBL) in a non-selected population of patients in a
large Canadian health region.
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Methods
Study population
Prior to a recent restructuring as Alberta Health Services,
The Calgary Health Region (CHR) administered virtually
all medical and surgical care to the residents of the cities
of Calgary and Airdrie and a large surrounding area (pop-
ulation 1.2 million) in the Province of Alberta, Canada.
All patients with bacteremias caused by EK-ESBL organ-
isms from January 1, 2000 to December 31, 2007 in the
CHR were included.
Study protocol
An active, surveillance cohort design was utilized. As pre-
viously described, surveillance for EK-ESBL bacteremias
was conducted by Calgary Laboratory Services [12].
International Statistical Classification of Disease and
Health Related Problems (ICD) codes were translated
into Charlson Comorbidity Scores using standardized
algorithms [13-15] and an online macro [16]. All antimi-
crobial therapies prescribed were determined using the
regional pharmacy database [17]. EK-ESBL infections
were defined by the isolation of these organisms from one
or more sets of aseptically obtained blood culture bottles.
The presence or absence of ESBL-producing E. coli or K.
pneumoniae  cultures obtained from non-blood sites
within ± 48 hours of the index incident blood culture
draw was also assessed. Repeated isolation from blood
within 365 days was considered to be the same incident
infection and thereafter as new episodes.
Empiric therapy was defined as that therapy initiated
prior to the availability of blood culture results and sensi-
tivities. Time to first therapy was defined as the time from
blood culture draw to receipt of the first dose of antibiot-
ics. Adequate therapy was defined by the receipt of a
standard parenteral dose of an antimicrobial to which the
organism was fully susceptible in vitro based on Clinical
and Laboratory Standards Institute (CLSI) breakpoints or
a standard oral dose of an antimicrobial with high bio-
availability by this route, to which the organism was also
fully susceptible. ESBL-producing organisms were
assumed to be resistant to cefazolin, ceftriaxone, ceftazi-
dime, aztreonam, and cefipime. If the patient was given
adequate antibiotics before or at the time of the blood
culture draw then the time to first adequate therapy was
recorded as zero hours. Definitions of nosocomial,
healthcare associated and community-acquired infec-
tions have been previously described [12].
Laboratory Methods
Clinical isolates were cultured, speciated, and tested for
antimicrobial susceptibility by standard techniques [18].
At Calgary Laboratory Services, all Enterobacteriaceae
isolates are routinely screened for ESBL production. Min-
imum inhibitory concentrations (MICs) were determined
by Vitek 2™ (Vitek AMS; bioMérieux Vitek Systems Inc.,
Hazelwood, MO). The quality control strains used for
this part of the study were E. coli ATCC 25922, E. coli
ATCC 35218 and Pseudomonas aeruginosa ATCC 27853.
The presence of ESBLs was detected in clinical isolates of
E. coli by using the CLSI criteria for ESBL screening and
disk confirmation tests [18]. Disks for ESBL confirmation
tests were obtained from Oxoid Inc. (Nepean, Ontario,
Canada). K. pneumoniae ATCC 700603 and E. coli ATCC
25922 were used as positive and negative controls,
respectively. Isoelectric focusing (IEF) which included
cefotaxime hydrolysis and inhibitor profiles in polyacryl-
amide gels was performed on freeze-thaw extracts as pre-
viously described [19]. Polymerase chain reaction (PCR)
amplification for blaCTX-Ms, blaOXAs, blaTEMs, blaSHV, was
carried out on the isolates with a GeneAmp 9700 Ther-
moCycler instrument (Applied Biosystems, Norwalk,
Con) using PCR conditions and primers as previously
described [19,20]. Automated sequencing was performed
on the PCR products with the ABI Prism 3100 Genetic
analyzer (Applied Bio-systems, Norwalk, Con) as previ-
ously described [21,22].
Statistical analysis
Analysis was performed using Stata version 10.0 (Stata
Corp, College Station, TX). Non-normally distributed
data were described using medians with interquartile
ranges (IQR) and compared using the Mann-Whitney
test. Categorical data were compared using the Fisher's
Exact or chi2 tests. P-values less than 0.05 were consid-
ered significant and those between 0.05 and 0.1 were con-
sidered to represent a trend.
Results
Population Characteristics
During the study period, 90 episodes of EK-ESBL bacter-
emias were identified. Detailed treatment and outcome
data were available for analysis in 79 (88%) episodes
occurring among 76 patients. Forty-four (56%) episodes
occurred in males and the median age was 70 (IQR 60.6-
70.1) years. The median crude Charlson Comorbidity
Score was 2 (IQR 0-3) and the median age-adjusted score
was 4 (IQR 2-6). Twenty-four (30%) of the bacteremias
were nosocomial; 33 (42%) were healthcare associated
and 22 (28%) were community acquired. The most com-
mon comorbid conditions were renal disease, n = 19
(24%); malignancy, n = 16 (20%); diabetes without com-
plications, n = 9 (11%), and diabetes with complications,
n = 10 (13%) as shown in Table 1.
Microbiological Characteristics
Of the 79 bacteremic episodes 72 (91%) were E. coli and 7
(9%) were K. pneumoniae. One Klebsiella pneumoniae
bacteremia was polymicrobial with Pseudomonas aerugi-Chaubey et al. BMC Research Notes 2010, 3:116
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Table 1: Characteristics of the population.
FACTOR CASE FATALITY WITH
FACTOR
CASE FATALITY 
WITHOUT
FACTOR
RELATIVE RISK
(95% CI)
P-VALUE
Male 6/44 (14%) 10/35 (29%) 0.48 (0.19-1.19) 0.09
Charlson ≥ median(4)
(Age Adjusted)
12/45 (27%) 4/34 (12%) 2.27 (0.80-6.41) 0.09
Cerebrovascular 
Disease
1/3 (33%) 15/76 (20%) 1.69 (0.32-8.91) NS
Congestive Heart 
Failure
1/7 (14%) 15/72 (21%) 0.69 (0.11-4.45) NS
Chronic Pulmonary 
Disease
0/1 (0%) 16/78 (21%) 0.00() NS
Dementia 1/4 (25%) 15/75 (20%) 1.25 (0.22-7.24) NS
Diabetes without 
complications
0/9 (0%) 16/70 (23%) 0.00() NS
Diabetes with 
complications
1/10 (10%) 15/69 (22%) 0.46 (0.07-3.11) NS
Paraplegia 0/1 (0%) 16/78 (21%) 0.00() NS
Mild Liver Disease 3/4 (75%) 13/75 (17%) 4.32 (2.04-9.17) 0.03
Severe Liver Disease 2/4 (50%) 14/75 (19%) 2.68 (0.90-7.95) NS
Malignancy 5/21 (24%) 11/58 (19%) 1.25 (0.49-3.19) NS
Metastatic 0/1 (0%) 16/78 (21%) 0.00() NS
Myocardial Infarction 1/3 (33%) 15/76 (20%) 1.69 (0.32-8.91) NS
Peripheral Vascular 
Disease
0/1 (0%) 16/78 (21%) 0.00() NS
Peptic Ulcer Disease 0/2 (0%) 16/77 (21%) 0.00() NS
Rheumatologic 2/4 (50%) 14/75 (19%) 2.68 (0.90-7.95) NS
Renal 5/19 (26%) 11/60 (18%) 1.43 (0.57-3.61) NS
Dialysis 2/5 (40%) 14/74 (19%) 2.11 (0.65-6.83) NSChaubey et al. BMC Research Notes 2010, 3:116
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nosa. One Escherichia coli bacteremia was polymicrobial
with a viridans group streptococcus. Neither of these sec-
ond organisms affected adequacy of antimicrobial ther-
apy as they were sensitive to all major classes of
antibiotics. Thirty-nine bacteremias (49%) were primary;
38 (48%) were from a urinary source; 2 (3%) resulted from
pneumonias and 1 (1%) patient had a biliary source. One
patient had two sources documented (one urinary and
the other biliary). Although typing was not performed for
K. pneumoniae isolates, E. coli ESBL's were typed as 1
CTX-M-2, 1 CTX-M-3, 27 CTX-M-14, 35 CTX-M-15, 5
SHV-2, 1 TEM-52 and 1 was unknown.
Description of therapy
The median time to initial empiric therapy was 4.9 (IQR
0-13.9) hours and the median time to first adequate anti-
biotic therapy was 41 (IQR 5.8-59.5) hours. Seventy-four
(94%) of episodes had received empiric antibiotic therapy
by 48 hours, but only 42 (53%) were prescribed an ade-
quate antibiotic regimen by this time point. Specific
details of empiric therapy and initial antibiotics chosen
are described in Table 2 and the adequacy of therapy and
first adequate antibiotics utilized are shown in Table 3.
Outcomes
Overall 63 cases (80%) survived to discharge. The case-
fatality rate associated with an episode of E. coli bactere-
mia was 22% (16/72) whereas this was 0% (0/7) for K.
pneumoniae. Those who received adequate therapy by 8
hours (6/22; 27% vs. 6/53; 11%; p = 0.088) and 24 hours
(7/28; 25% vs. 5/42; 12%; p = 0.096) trended towards a
higher likelihood of death. However, there was no signifi-
cant difference in mortality when comparing those
patients who were adequately treated to those inade-
quately treated by 48 hours (9/42; 21% vs. 7/37; 19%; p =
1.0). Statistical trends toward a worse clinical outcome
was associated with the following factors: age-adjusted
Charlson score greater than the median (12/45; 27% vs. 4/
34; 12% mortality; p = 0.087), female gender (10/35; 28.5%
vs. 6/38; 13.6% mortality; p = 0.087); and having been
Table 2: Description of empiric therapy *.
FACTOR CASE FATALITY WITH 
FACTOR
CASE FATALITY 
WITHOUT FACTOR
RELATIVE RISK (95% CI) P-VALUE
Empiric by t = 0 7/29 (24%) 9/50 (18%) 1.34 (0.56-3.22) NS
Empiric by t = 8 hours 12/48 (25%) 4/31 (13%) 1.94 (0.69-5.47) NS
Empiric by t = 24 hours 14/68 (21%) 2/11 (18%) 1.13 (0.30-4.32) NS
Empiric by t = 48 hours 15/74 (20%) 1/5 (20%) 1.01 (0.17-6.20) NS
Empiric at t > 48 hours 0/3 (0%) 16/76 (21%) 0.00 NS
Never received empiric therapy. 0/1 (0%) 16/78 (21%) ... ...
Empiric Treatment Class
Carbapenem 0/10 (0%) 16/69 (24%) 0.00 () 0.09
Aminoglycoside 1/7 (14%) 15/72 (21%) 0.67 (0.10-4.41) NS
Fluoroquinolone 3/13 (23%) 13/66 (20%) 1.17 (0.39-3.54) NS
Beta-lactam/Beta-lactamase 
inhibitor combination
6/16 (38%) 10/63 (16%) 2.36 (1.01-5.53) 0.06
Cephalosporin 5/30 (17%) 11/49 (22%) 0.74 (0.29-1.93) NS
Beta-lactam 0/5 (0%) 16/74 (22%) 0.00 () NS
* Empiric therapy was defined as that therapy initiated prior to the availability of blood culture results and sensitivities.Chaubey et al. BMC Research Notes 2010, 3:116
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treated empirically with a beta-lactam/beta-lactamase
inhibitor combination (6/16; 38% vs. 10/53; 18% mortal-
ity; p = 0.063). There was no association between ESBL
type and mortality. Of 10 patients empirically treated
with a carbapenem none died vs. 16/53 (30%) patients
having died who were not empirically treated with a car-
bapenem (p = 0.089). Of note empiric cephalosporin
therapy was not associated with a worse outcome (5/30;
16% vs. 11/49; 22%, p = 0.375). The case-fatality rate was
highest for patients with nosocomial infections (38%; 9/
24), followed by those with healthcare associated infec-
tions (15%; 5/33) and community-acquired infections
(9%; 2/22 patients); p = 0.046.
Discussion
This study describes the contemporary treatment of
ESBL-producing  E. coli and  K. pneumoniae in a large
Canadian health region. Although we found high rates of
inadequacy of therapy, we did not observe an increased
risk for death associated with inadequate therapy.
It should be noted that our data was also analyzed using
only patients with E. coli bacteremia as K. pneumoniae
represented such a small proportion of the overall cohort
(data not shown). The major conclusions were
unchanged. The small number of K. pneumoniae isolates
included prohibits generalization to bacteremias caused
by this organism.
It is a curious finding that when comparing those who
received adequate therapy by 8 and 24 hours to those that
were inadequately treated that there was a trend in favour
of inappropriate therapy. It is widely accepted that early
appropriate antibiotic therapy should be protective
[23,24]. We speculate that this observation may be
explained by sicker patients (who are at higher risk for
death) may be more likely to get broader and more
prompt empiric antimicrobial as a result of their clinical
condition. However, it is a limitation of our study that we
did not collect data to measure severity of illness to con-
firm this suspicion. The possibility also exists that this
was a spurious finding, as the difference was no longer
Table 3: Description of adequacy of therapy **.
FACTOR CASE FATALITY WITH 
FACTOR
CASE FATALITY 
WITHOUT FACTOR
RELATIVE RISK (95% CI) P-VALUE
Adequate by t = 0 1/11 (9%) 15/68 (22%) 0.41 (0.06-2.81) NS
Adequate by t = 8 hours 6/22 (27%) 10/57(18%) 1.55 (0.64-3.76) 0.09
Adequate by t = 24 hours 7/28 (25%) 9/51 (18%) 1.42 (0.59-3.39) 0.10
Adequate by t = 48 hours 9/42 (21%) 7/37 (18%) 1.13 (0.47-2.74) NS
Adequate at t > 48 hours 3/33 (9%) 13/46 (28%) 0.32 (0.10-1.04) NS
Never received adequate therapy 4/4 (100%) 12/75 (16%) 6.25 (3.72-10.5) 0.01
First Adequate Antibiotic Choice
Beta-lactam/Beta-lactamase 
inhibitor combination
6/28 (21%) 10/51 (20%) 1.09 (0.44-2.69) NS
Carbapenem 4/30 (13%) 12/49 (24%) 0.54 (0.19-1.53) NS
Fluoroquinolone 1/4 (25%) 15/75 (20%) 1.25 (0.22-7.24) NS
Aminoglycoside 1/10 (10%) 15/69 (22%) 0.46 (0.07-3.11) NS
Sulfa 1/3 (33%) 15/76 (20%) 1.69 (0.32-8.91) NS
** Adequate therapy was defined by the receipt of a standard parenteral dose of an antimicrobial to which the organism was fully susceptible 
in vitro based on Clinical and Laboratory Standards Institute (CLSI) breakpoints or a standard oral dose of an antimicrobial with high 
bioavailability by this route, to which the organism was also fully susceptible.Chaubey et al. BMC Research Notes 2010, 3:116
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observed by 48 hours of observation. It must be recogn-
ised that our study involved a relatively small cohort of
patients and was underpowered to detect a clinically sig-
nificant difference in outcome.
In our study the most common type of ESBL enzyme is
the CTX-M type, specifically in our region CTX-M-14
and CTX-M-15. CTX-M type enzymes in general and
CTX-M-15 in particular have been shown in previous lit-
erature [1] to be the most widely disseminated ESBL
enzymes. Our study reaffirms these finding. More studies
are needed to determine why these ESBL types are more
prevalent than others.
Piperacillin/tazobactam is the most commonly used
broad-spectrum antibiotic in our region (data not
shown). Our study suggests a poorer prognosis experi-
enced by patients treated with this agent and this has
been previously been demonstrated by others [25,26]. It is
notable that 5 of 6 patients treated with piperacillin/
tazobactam who died were sensitive by CLSI (< = 16 mg/
L) and EUCAST (< = 8 mg/L) breakpoints. These data
suggest that piperacillin/tazobactam should not be used
for serious infections due to EK-ESBL even in the setting
of in vitro susceptibility. Most authors agree that carbap-
enems are the drugs of choice [26-29] for serious infec-
tions caused by organisms that elaborate ESBLs. Our
observation that all 10 patients who received empiric car-
bapenem therapy survived, while not proving, supports
this principle. Overall EK-ESBL bacteremias are relatively
uncommon. The challenge to researchers and clinicians is
to select patients appropriately for early broad-spectrum
therapy in an attempt to improve outcome while mini-
mizing over treatment and the associated risks of anti-
microbial resistance.
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